GO:0032089 NACHT domain binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032089 (NACHT domain binding) is a molecular function describing the selective binding of a protein to a NACHT domain, the nucleotide-binding module found in NAIP, CIITA, HET-E and TP1 proteins.
• The NACHT domain contains seven conserved motifs, including an ATP/GTPase-specific P-loop and a Mg2+-binding site, which together drive nucleotide-dependent oligomerization.
• NACHT domain binding is central to NLRP3 inflammasome activation, where NEK7 binds the NLRP3 NACHT domain to license assembly.
• Small-molecule inhibitors such as MCC950 and oridonin directly engage the NLRP3 NACHT domain or its ATP-hydrolysis motif, validating this domain as a drug target.
• Bacterial NLR-related proteins that use NACHT-like domains protect against phage, showing deep evolutionary conservation of NACHT domain interactions.
• Dysregulated NACHT domain-dependent inflammasome signaling is linked to gout, inflammatory disease and innate immune pathology.
Description
GO:0032089, NACHT domain binding, is a molecular function term that describes the binding of a protein to a NACHT domain, the central nucleotide-binding module of the NAIP, CIITA, HET-E and TP1 protein family. The NACHT domain is defined by seven conserved motifs, including an ATP/GTPase-specific P-loop and a Mg2+-binding site, which allow the domain to hydrolyze nucleotides and switch between inactive and active conformations. Because this binding event controls whether innate immune sensors assemble into signaling platforms, it is a focal point for research on inflammation, host defense and therapeutic intervention. In practical terms, NACHT domain binding is the molecular handshake that determines whether an NLR protein stays autoinhibited or recruits partners to form an inflammasome. Structural and biochemical studies have shown that the NLRP3 NACHT domain adopts a closed conformation in the presence of inhibitors and an open, activation-competent state when licensed by NEK7. This conformational logic explains why mutations or chemical probes that alter NACHT domain interactions can profoundly change inflammatory output. For researchers, GO:0032089 provides a precise annotation axis for interrogating protein-protein interactions, nucleotide-dependent conformational changes and drug mechanism of action. It also connects cell biology to disease: gout and other inflammatory conditions involve genetic and epigenetic regulation of innate immune responses that depend on NACHT domain function. Understanding NACHT domain binding therefore bridges structural biology, immunology and translational pharmacology.
NACHT domain binding At A Glance
| GO ID | GO:0032089 |
|---|---|
| GO term | NACHT domain binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to a NACHT (NAIP, CIITA, HET-E and TP1) domain, a nucleotide-binding module with seven conserved motifs including an ATP/GTPase-specific P-loop and a Mg2+-binding site |
| Domain architecture | NACHT domain contains seven conserved motifs, an ATP/GTPase-specific P-loop and a Mg2+-binding site |
| Representative binders | NEK7 binds the NLRP3 NACHT domain to license inflammasome activation |
| Pharmacological probes | MCC950 targets the NLRP3 ATP-hydrolysis motif; oridonin covalently inhibits NLRP3 |
| Evolutionary scope | NACHT-like domains occur in bacterial NLR-related proteins that protect against phage |
What Is GO:0032089?
In our own words, NACHT domain binding (GO:0032089) is the molecular function of selectively and non-covalently interacting with a NACHT domain, a conserved nucleotide-binding module found in proteins such as NAIP, CIITA, HET-E and TP1. The NACHT domain itself comprises seven distinct conserved motifs, including an ATP/GTPase-specific P-loop, a Mg2+-binding site and five additional motifs that coordinate nucleotide hydrolysis and oligomerization. Binding to this domain can stabilize an inactive state, as seen with NLRP3 inhibitors, or promote an active state, as seen with NEK7 licensing.
Why Is NACHT domain binding Important in Cell Biology?
NACHT domain binding matters because it is the decisive interaction that controls assembly of NLRP3 and related inflammasomes, which are central to innate immunity and to inflammatory disease. Structural work shows that the NLRP3 NACHT domain can be locked in an inhibited state by small molecules, while NEK7 binding licenses the active conformation, making this binding interface a validated drug target. Beyond immunology, NACHT-like domains in bacterial proteins defend against phage, underscoring the broad biological significance of NACHT domain interactions.
• Controls NLRP3 inflammasome activation through NEK7 binding to the NACHT domain.
• Provides a structural basis for inflammasome inhibition by small molecules such as MCC950.
• Enables covalent inhibition of NLRP3 by oridonin, linking NACHT domain chemistry to anti-inflammatory activity.
• Underpins innate immune responses relevant to gout and other inflammatory diseases.
• Represents a conserved nucleotide-dependent switch with ATP/GTPase P-loop and Mg2+-binding motifs.
• Is a target for therapeutic development in inflammatory disease.
• Illustrates evolutionary conservation through bacterial NLR-related phage defense proteins.
• Supports research on protein-protein interaction specificity and conformational regulation.
Molecular Mechanism of NACHT domain binding
Nucleotide-dependent conformational switching
In simple terms: The NACHT domain acts like a switch that flips between off and on depending on nucleotide binding and hydrolysis.
The NACHT domain contains an ATP/GTPase-specific P-loop and a Mg2+-binding site, allowing it to bind and hydrolyze nucleotides. Crystal structures of the NLRP3 NACHT domain with an inhibitor reveal how nucleotide-dependent conformational states define the mechanism of inflammasome inhibition. MCC950 directly targets the NLRP3 ATP-hydrolysis motif, demonstrating that nucleotide handling within the NACHT domain is essential for activation.
NEK7 licensing of NLRP3
In simple terms: A partner protein called NEK7 must bind the NACHT domain before NLRP3 can assemble into its active platform.
Structural analysis shows that NEK7 binds the NLRP3 NACHT domain and licenses inflammasome activation through a defined interface. This binding event converts NLRP3 from an autoinhibited state to an assembly-competent state, making NACHT domain binding a checkpoint for innate immune signaling.
Small-molecule engagement of the NACHT domain
In simple terms: Drug-like molecules can stick to the NACHT domain and jam the switch in the off position.
Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity, showing that chemical modification of the NACHT domain can block signaling. MCC950 binds the NLRP3 ATP-hydrolysis motif, providing a direct example of NACHT domain-targeted inhibition. These findings validate NACHT domain binding as a druggable molecular function.
Evolutionary conservation in bacterial NLR-related proteins
In simple terms: Even bacteria use NACHT-like domains to fight off viruses, showing how ancient this binding function is.
Bacterial NLR-related proteins protect against phage, indicating that NACHT-like domain interactions are conserved across distant branches of life. This conservation supports the view that NACHT domain binding is a fundamental protein interaction module rather than a vertebrate-specific innovation.
Key Genes Involved in GO:0032089 NACHT domain binding
The following genes and proteins are directly implicated in NACHT domain binding or in the structural and pharmacological studies that define this molecular function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NLRP3 | Contains a NACHT domain that binds NEK7 and nucleotides to drive inflammasome assembly | Central target for structural and inhibitor studies of NACHT domain binding |
| NEK7 | Binds the NLRP3 NACHT domain to license inflammasome activation | Key partner protein defining the activation-competent NACHT interface |
| NAIP | NACHT-domain-containing protein family member | Namesake of the NACHT acronym and model for domain architecture |
| CIITA | NACHT-domain-containing transcriptional regulator | Namesake of the NACHT acronym and model for domain architecture |
| HET-E | NACHT-domain-containing protein | Namesake of the NACHT acronym and model for domain architecture |
| TP1 | NACHT-domain-containing protein | Namesake of the NACHT acronym and model for domain architecture |
| MCC950 | Small molecule targeting the NLRP3 ATP-hydrolysis motif | Pharmacological probe for NACHT domain function |
| Oridonin | Covalent NLRP3 inhibitor | Chemical tool for interrogating NACHT domain binding |
| NLRP3 ATP-hydrolysis motif | Nucleotide-processing element within the NACHT domain | Direct binding site for MCC950 |
| Bacterial NLR-related proteins | NACHT-like domain proteins that protect against phage | Evolutionary model for NACHT domain interactions |
| Inflammasome complex | Higher-order assembly nucleated by NACHT domain interactions | Readout for NACHT domain binding function |
| Gout-associated innate immune pathway | Inflammatory signaling dependent on inflammasome activation | Disease context for NACHT domain binding |
How Is NACHT domain binding Regulated?
NACHT domain binding is regulated by nucleotide occupancy and partner protein availability. The NACHT domain's ATP/GTPase P-loop and Mg2+-binding site couple nucleotide hydrolysis to conformational change, and inhibitors such as MCC950 act by targeting the ATP-hydrolysis motif. NEK7 binding provides a licensing step that is required for NLRP3 activation, so the abundance and localization of NEK7 regulate whether NACHT domain binding leads to inflammasome assembly. Covalent modification by oridonin further shows that the NACHT domain can be chemically regulated. In disease contexts such as gout, genetic and epigenetic factors shape the innate immune response that depends on these interactions.
NACHT domain binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NLRP3 | Inflammatory disease and inflammasome-driven pathology | NLRP3 knockout and point-mutation cell models to test NACHT domain binding |
| NEK7 | Innate immune activation licensing | NEK7 knockout and tagged knock-in models to map NACHT domain interaction |
| NLRP3 ATP-hydrolysis motif | Pharmacological inhibition of inflammasome | Point-mutation knock-in of the ATP-hydrolysis motif to test MCC950 binding |
| NLRP3 | Gout-associated innate immune response | Overexpression and knockout models in immune cells |
| Bacterial NLR-related proteins | Phage defense | Bacterial knockout and overexpression models for NACHT-like domain function |
Inflammatory disease and inflammasome-driven pathology
NACHT domain binding is required for NLRP3 inflammasome activation, and targeting the NLRP3 inflammasome is an active strategy for inflammatory disease therapy. Small molecules that bind the NACHT domain or its ATP-hydrolysis motif, such as MCC950 and oridonin, suppress inflammasome activity, confirming the therapeutic relevance of this molecular function.
Gout and innate immune dysregulation
Gout involves genetic and epigenetic regulation of the innate immune response, a pathway in which inflammasome activation depends on NACHT domain interactions. Because NEK7 binding to the NLRP3 NACHT domain licenses activation, perturbations in this binding step can influence inflammatory flares.
Host defense and evolutionary conflict
Bacterial NLR-related proteins that use NACHT-like domains protect against phage, linking NACHT domain binding to host defense across kingdoms. This evolutionary perspective reinforces the importance of NACHT domain interactions in immunity and microbial conflict.
From NACHT domain binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NLRP3 NACHT domain binding abolish inflammasome activation? | NLRP3 knockout cell model |
| Which residues in the NACHT domain mediate NEK7 binding? | Point-mutation knock-in of NLRP3 NACHT domain residues |
| Can a tagged NACHT domain be used to purify binding partners? | Tagged knock-in of NLRP3 NACHT domain |
| Does overexpression of NEK7 enhance NACHT domain-dependent activation? | NEK7 overexpression cell model |
| Does mutation of the ATP-hydrolysis motif alter inhibitor sensitivity? | Point-mutation knock-in of the NLRP3 ATP-hydrolysis motif |
| Do bacterial NACHT-like proteins protect against phage? | Bacterial knockout and overexpression models |
How to Study the NACHT domain binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography | Three-dimensional structure of NACHT domain-inhibitor complexes | Defining the binding pocket and inhibitory mechanism |
| Cryo-EM or structural analysis | Conformation of NEK7-licensed NLRP3 | Mapping the NACHT domain activation interface |
| ATP-hydrolysis assay | Nucleotide processing by the NACHT domain | Testing MCC950 targeting of the ATP-hydrolysis motif |
| Covalent inhibitor labeling | Irreversible modification of NLRP3 | Characterizing oridonin activity |
| Knockout cell models | Requirement for NACHT domain binding in inflammasome activation | Loss-of-function studies |
| Point-mutation knock-in | Residue-level contribution to NACHT domain binding | Structure-function mapping |
| Overexpression models | Gain-of-function effects on inflammasome signaling | Testing NEK7 or NLRP3 dosage |
| Phage protection assay | Antiviral function of bacterial NLR-related proteins | Evolutionary study of NACHT-like domains |
Structural biology of NACHT domain complexes
Crystal structures of the NLRP3 NACHT domain with an inhibitor define the mechanism of inflammasome inhibition and reveal the binding pocket. Structural analysis of NEK7-licensed NLRP3 provides a framework for understanding how NACHT domain binding triggers activation.
Biochemical and pharmacological assays
MCC950 directly targets the NLRP3 ATP-hydrolysis motif, so nucleotide hydrolysis assays and inhibitor-binding assays are used to measure NACHT domain function. Oridonin's covalent inhibition of NLRP3 provides a complementary chemical biology approach.
Genetic and cellular models
Knockout, point-mutation and overexpression models are used to test whether specific NACHT domain residues are required for inflammasome assembly. Gout-related innate immune responses can be modeled in immune cells to connect NACHT domain binding to disease.
Evolutionary and microbial assays
Bacterial NLR-related proteins that protect against phage can be studied with knockout and overexpression experiments to test NACHT-like domain function.
How CRISPR Can Be Used to Study GO:0032089 NACHT domain binding
Knockout
CRISPR knockout of NLRP3 or NEK7 can abolish NACHT domain-dependent inflammasome activation, providing a clean loss-of-function test for GO:0032089. Knockout models are also useful for confirming that a candidate binding partner is required for the NACHT domain interaction.
Point Mutation
Point-mutation knock-in of residues in the NLRP3 NACHT domain or ATP-hydrolysis motif allows precise testing of which amino acids mediate NEK7 binding or inhibitor sensitivity. Such models distinguish binding-interface residues from catalytic nucleotide-handling residues.
Knock-in
Tagged knock-in of the NLRP3 NACHT domain enables affinity purification and proteomic identification of binding partners under native conditions. Knock-in of reporter or affinity tags also supports imaging and interaction studies.
Overexpression
Overexpression of NEK7 or NLRP3 can amplify NACHT domain-dependent signaling and reveal gain-of-function phenotypes. Overexpression is also used in bacterial systems to test whether NACHT-like proteins protect against phage.
How EDITGENE Supports NACHT domain binding Research
Researchers studying NACHT domain binding-related genes often need to determine whether a candidate gene is causally involved in inflammasome activation, inhibitor response or innate immune signaling. EDITGENE provides the CRISPR cell models and screening services needed to move from correlation to mechanism.
Contact EDITGENE today to design your custom CRISPR model for NACHT domain binding research.
Frequently Asked Questions About NACHT domain binding
What is NACHT domain binding?
NACHT domain binding (GO:0032089) is the molecular function of binding to a NACHT domain, a conserved nucleotide-binding module found in NAIP, CIITA, HET-E and TP1 proteins.
What is the GO ID for NACHT domain binding?
The GO ID is GO:0032089, and the ontology aspect is molecular_function.
What genes are involved in NACHT domain binding?
Key genes include NLRP3 and NEK7, along with the namesake NACHT-domain proteins NAIP, CIITA, HET-E and TP1.
How does NEK7 interact with the NLRP3 NACHT domain?
NEK7 binds the NLRP3 NACHT domain and licenses inflammasome activation through a defined structural interface.
What drugs target the NACHT domain?
MCC950 targets the NLRP3 ATP-hydrolysis motif, and oridonin is a covalent NLRP3 inhibitor that engages the NACHT domain.
Why is NACHT domain binding important for inflammation?
It controls assembly of the NLRP3 inflammasome, a central innate immune platform in inflammatory disease.
Is NACHT domain binding conserved in bacteria?
Yes, bacterial NLR-related proteins with NACHT-like domains protect against phage, showing evolutionary conservation.
What diseases are linked to NACHT domain binding?
Inflammatory diseases and gout-related innate immune responses are linked to NACHT domain-dependent inflammasome activation.
How can I study NACHT domain binding in the lab?
Common approaches include structural biology, ATP-hydrolysis assays, knockout and point-mutation cell models, and overexpression studies.
What CRISPR models are useful for NACHT domain binding research?
Knockout, point-mutation knock-in, tagged knock-in and overexpression models are all used to dissect NACHT domain interactions.
Conclusion
GO:0032089 NACHT domain binding captures a decisive molecular interaction that governs NLRP3 inflammasome activation and related innate immune signaling. Structural, pharmacological and genetic studies have converged on the NACHT domain as a nucleotide-dependent switch that can be licensed by NEK7 or locked by inhibitors such as MCC950 and oridonin. Its conservation in bacterial NLR-related proteins further highlights its fundamental biological importance. For researchers, NACHT domain binding offers a tractable axis for mechanistic and translational work, from mapping binding interfaces to testing therapeutic candidates in inflammatory disease and gout. CRISPR-based knockout, point-mutation, knock-in and overexpression models provide the experimental toolkit needed to move this field forward.
References
- 1. Cabral JE et al.. 2025. Targeting the NLRP3 inflammasome for inflammatory disease therapy.. Trends Pharmacol Sci 46(6):503-519 PMID: 40374417
- 3. Dekker C et al.. 2021. Crystal Structure of NLRP3 NACHT Domain With an Inhibitor Defines Mechanism of Inflammasome Inhibition.. J Mol Biol 433(24):167309 PMID: 34687713
- 4. Sharif H et al.. 2019. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome.. Nature 570(7761):338-343 PMID: 31189953
- 5. He H et al.. 2018. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity.. Nat Commun 9(1):2550 PMID: 29959312
- 6. Coll RC et al.. 2019. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition.. Nat Chem Biol 15(6):556-559 PMID: 31086327
- 7. Kibby EM et al.. 2023. Bacterial NLR-related proteins protect against phage.. Cell 186(11):2410-2424.e18 PMID: 37160116
- 8. de Lima JD et al.. 2023. Genetic and Epigenetic Regulation of the Innate Immune Response to Gout.. Immunol Invest 52(3):364-397 PMID: 36745138
